Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies

News : Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Xlife Sciences AG: Xlife Sciences expands its project portfolio

12/03/2020 | 01:31am EST

DGAP-News: Xlife Sciences AG / Key word(s): Investment/Miscellaneous
Xlife Sciences AG: Xlife Sciences expands its project portfolio

03.12.2020 / 07:30
The issuer is solely responsible for the content of this announcement.


Xlife Sciences AG: Xlife Sciences expands its project portfolio

Two new project companies offer strong synergy potential

Xlife Sciences expands its project portfolio to 23 projects by adding Panmabs GmbH and Xarma Life Science GmbH, both based in Mainz. According to the management of Xlife Sciences this creates significant synergies between various project companies, particularly in the treatment of life-threatening diseases and in fighting multi-resistant bacteria.

About Panmabs GmbH

Panmabs aims to become a leading specialist in treating pathologies that arise from epidemic spreading of life-threatening pathogens like the worldwide rising multi-drug resistant bacteria (MRSA) and other infectious threats with lacking or insufficient treatment options. In particular due to the lack of or poor treatment options for such resistant pathogens, the management of Xlife sees enormous market potential in this area. In this context, Panmabs will develop different therapeutic anti-viral and anti-bacterial drug candidates (monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), small molecules) from other third parties and Xlife portfolio companies.

About Xarma Life Science GmbH

Xarma Life Science GmbH will develop first-in-class functional and modulatory drugs (mAbs and ADCs), targeting complex membrane receptors like G-protein coupled receptors (GPCRs), ion channels and others for the treatment of circulatory, immunologic and oncogenic diseases with unmet medical needs. Within the mentioned fields, Xarma will allocate significant resources for the investigation of new routes towards novel personalised treatment options for currently untreatable diseases.

About Xlife Sciences AG

Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch

For media inquiries:

Oliver R. Baumann, CEO Xlife Sciences AG, Tel. +41 44 385 84 60, oliver.baumann@xlifesciences.com



03.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Xlife Sciences AG
Klausstrasse 19
8008 Zürich
Switzerland
Phone: 0041 44 385 84 60
E-mail: info@xlifesciences.ch
Internet: www.xlifesciences.ch
ISIN: CH0461929603
WKN: A2PK6Z
Listed: Regulated Unofficial Market in Frankfurt, Munich
EQS News ID: 1152456

 
End of News DGAP News Service

1152456  03.12.2020 

fncls.ssp?fn=show_t_gif&application_id=1152456&application_name=news&site_id=zonebourse_sftp

© EQS 2020
Latest news "Companies"
12:20aSGS : AFIRM LabTAC appoints Dr Helmut Krause, SGS
PU
12:17aEast-bound naphtha to rise to about 2 mln T each in Jan, Feb
RE
12:13aHISCOX : Launches New Dreams Advertising Campaign Spotlighting Small Business Owners
PU
12:11aTOKAI : Certification of "Eruboshi (Third Stage)" based on the Act on Promotion of Women's Participation and Advancement in the Workplace (176KB)
PU
12:10aTECHNIPFMC : Announces Offering of $850,000,000 Senior Notes
BU
12:09aGLOBALDATA : Big-ticket deals take back seat as caution grips APAC VC funding landscape during Q4 2020, finds GlobalData
PU
12:09aGLOBALDATA : Morgan Stanley top M&A financial adviser in Asia-Pacific for 2020, finds GlobalData
PU
12:02aUNIVERSAL PROPTECH : An Integrated and Holistic Approach Stops the Spread of Covid-19 in Public Facilities
PU
12:02aMCAFEE : Takes Another Step Toward Global Support for Organizations in Need of Leading Managed Threat Detection and Response
BU
01/18Triterras Authorizes $50 Million Share Repurchase Program and Provides Update on Recent Events
GL
Latest news "Companies"